Current studies have demonstrated that tau is involved in regulating the pathology of stroke through multiple pathological pathways, such as oxidative stress, neuroinflammation, excitotoxicity, autophagy, and mitochondrial dysfunction. These findings suggest that modulation of tau is a potential therapeutic pathway for stroke. However, there are few studies on the development of stroke drugs targeting tau. Ace Neuroscience offers a range of services, from screening potential stroke drugs targeting tau and the pharmacological evaluation of drug candidates, to data analysis. Our goal is to facilitate the development of your stroke drug targeting tau.
The current study found that stroke leads to elevated levels of total tau in human cerebrospinal fluid. And a combination of different studies found that inhibition of tau expression would in turn ameliorate stroke by modulating pathological pathways such as oxidative stress, excitotoxicity, angiogenesis, and mitochondrial dysfunction. Therefore, we first obtain tau inhibitors by high-throughput screening and then evaluate their pharmacological activity against stroke. In view of this, Ace Neuroscience has established a sophisticated screening service platform for tau inhibitors.
We have demonstrated the inhibitory effect of tau inhibitor candidates on tau. Immediately after, we offer various pharmacological activity evaluation services to test the therapeutic effect of candidate tau inhibitors on stroke.
Regarding other directions of targeting tau to develop stroke drugs, such as tau aggregation blockers, we also offer complete drug development services. If you would like to learn more about our services, please feel free to contact us.
We are committed to accelerating progress in stroke research and drug development.